Citation: | ZHANG Kao-fei, WU Mei-lin, WANG Yang-kui, FU Chang-fang. Evaluation and Analysis of The Rationality of Adjuvant Chemotherapy for Colon Cancer Patients in Jingxian Hospital in 2015[J]. Journal of Evidence-Based Medicine, 2019, 19(1): 59-64. DOI: 10.12019/j.issn.1671-5144.2019.01.015 |
[1] |
国家卫生和计划生育委员会. 关于加强肿瘤规范化诊疗管理工作的通知[S]. 国卫办医发(2016)7号. 2016-03-22.
|
[2] |
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology:Colon cancer(2018.V1)[EB/OL]. https://www.nccn.org/
|
[3] |
国家卫生计生委医政医管局, 中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2017版)[J]. 中华胃肠外科杂志, 2018, 21(1): 92-106.
|
[4] |
蒲兵, 谢法东, 孙波, 等. 抗肿瘤合理用药评价体系的建立[J]. 中国医院药学杂志, 2014,34(2):143-146.
|
[5] |
O'CONNELL J B, MAGGARD M A, KO C Y. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging[J]. J NatI Cancer Inst, 2004, 96(19): 1420-1425.
|
[6] |
ANDRÉ T, BONI C, MOUNEDJI-BOUDIAF L, et al.Oxaliplatin, Fluorouracil, and Leucovorin as adjuvant treatment for colon cancer[J]. N Engl J Med, 2004,350(23): 2343-2351.
|
[7] |
de GRAMONT A, BONI C, NAVARRO M, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years[J]. J Clin Oncol, 2007, 25(18 S): 4007.
|
[8] |
ANDRÉ T, BONI C, NAVARRO M, et al.Improved overall survival with Oxaliplatin, Fluorouracil, and Leucovorin as adjuvant treatment in stage Ⅱor Ⅲcolon cancer in the MOSAIC trial[J]. J Clin Oncol, 2009, 27(19): 3109-3116.
|
[9] |
COMPTON C C, FIELDING L P, BURGART L J, et al.Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999[J]. Arch Pathol Lab Med, 2000,124(7): 979-994.
|
[10] |
BENSON A B, SCHRAG D, SOMERFIELD M R, et al.American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stageⅡcolon cancer[J]. J Clin Oncol, 2004, 22(16):3408-3419.
|
[11] |
SARGENT D J, MARSONI S, MONGES G, et al.Defective mismatch repair as a predictive marker for lack of efficacy of Fluorouracil-based adjuvant therapy in colon cancer[J]. J Clin Oncol, 2010, 28(20): 3219-3226.
|
[12] |
ROTH A D, DELORENZI M, TEJPAR S, et al.Integrated analysis of molecular and clinicalprognostic factors in stage Ⅱ/Ⅲ colon cancer[J]. J Natl Cancer Inst, 2012, 104(21):1635-1646.
|
[13] |
秦琼. Ⅱ、Ⅲ期结肠癌根治术后复发转移多因素分析及DNA错配修复(MMR)蛋白状态对预后和疗效预测的影响[D]. 北京协和医学院, 2013.
|
[14] |
邰宵辉, 张玲芳, 张旭霞, 等. 我院2011-2014年结直肠癌患者化疗用药分析[J]. 中国药房, 2015, 26(32): 4485-4487.
|
[15] |
BIAGI J J, RAPHAEL M J, MACKILLOP W J, et al.Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: A systematic review and meta-analysis[J]. JAMA, 2011, 305(22): 2335-2342.
|
[16] |
国家卫生计生委合理用药专家委员会. 消化道恶性肿瘤合理用药指南[J]. 中国合理用药探索杂志, 2017, 14(9): 5-54.
|